Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2025Open Access

A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist

View Full Paper
Ask AI
Bookmark
Share

Authors

BVBinje VickVJVindi JurinovićKKKristina Kuhbandner

Discussion

Loading...

Member takes

Overview

Preclinical models demonstrate effective replication of AML biology and treatment responses, highlighting their clinical potential.

Key Points

  • Models derived from 137 patients show greater fidelity to AML biology than traditional cell lines, suggesting improved research outcomes.
  • Comprehensive analyses confirm ACKNOWLEDGEMENT: patient-derived xenografts faithfully replicate aggressive relapsed AML characteristics.
  • Real-time in vivo imaging allows for monitoring treatment responses in preclinical trials, enhancing research reliability.
  • Long-term treatment outcomes reveal cytarabine significantly reduces leukemia cell proliferation, suggesting potential therapeutic insights.

Cite This Study

Vick et al. (2025) studied this question.

synapsesocial.com/papers/68da58e0c1728099cfd116b7https://doi.org/10.1101/2025.09.26.677299
View Full Paper
Ask AI
Bookmark
Share